Comparative Biosciences, Inc. (CBI), a leading preclinical Contract Research Organization (CRO), has demonstrated expertise in all phases of the drug development process in preclinical contract ocular studies. Our highly specialized staff is experienced in providing exploratory/proof-of-concept, GLP toxicology, pharmacokinetics, in vivo animal models, pharmacology, and histopathology/immunohistochemistry.
Due to CBI’s unique and extensive experience in preclinical contract ocular studies and state-of-the-art facilities, we have the skill and expertise to accelerate new ocular drugs from discovery through the drug development process to regulatory submission. CBI is committed and dedicated to providing state-of-the-art ophthalmology research and offers a complete range of services to pharmaceutical, biotech, and medical device companies.